CORE--BIOCHEMISTRY AND BIOTECHNOLOGY

$553,190P30FY2007CANIH

Fox Chase Cancer Center, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 39604567 Paper 39602533 Paper 39554190 Paper 39546469 Paper 39521739 Paper 39514554 Paper 39371220 Paper 39345610 Paper 39343653 Paper 39223207 Paper 39207123 Paper 39189642 Paper 39148468 Paper 39137728 Paper 39072643 Paper 39060143 Paper 39013784 Paper 39003201 Paper 38982062 Paper 38976159 Paper 38963567 Paper 38914477 Paper 38871720 Paper 38865671 Paper 38853421 Paper 38835516 Paper 38815457 Paper 38811332 Paper 38798370 Paper 38766032 Paper 38747616 Paper 38678525 Paper 38659828 Paper 38639476 Paper 38638131 Paper 38600381 Paper 38586274 Paper 38586042 Paper 38559274 Paper 38547779 Paper 38539515 Paper 38464238 Paper 38452871 Paper 38432028 Paper 38421650 Paper 38377387 Trial NCT04290585 Trial NCT03177057 Trial NCT02594826 Trial NCT02132884 Trial NCT02132858 Trial NCT02132845 Trial NCT02110953 Trial NCT02092714 Trial NCT02050009 Trial NCT01982591 Trial NCT01962948 Trial NCT01934179 Trial NCT01840150 Trial NCT01462630 Trial NCT01316757 Trial NCT01212822 Trial NCT00750009 Trial NCT00509626 Trial NCT00458588 Trial NCT00436397 Trial NCT00433524 Trial NCT00084591 Trial NCT00084539 Trial NCT00084526 Trial NCT00084513 Trial NCT00066677 Trial NCT00062322 Trial NCT00062309 Trial NCT00043108 Trial NCT00039520 Trial NCT00039507 Trial NCT00022308 Trial NCT00021398 Trial NCT00021372 Trial NCT00021346 Trial NCT00021333 Trial NCT00021320 Trial NCT00005037 Trial NCT00003264 Trial NCT00003263 Trial NCT00003109 Patent 9533040 Patent 9182383 Patent 9101603 Patent 8980258 Patent 8685658 Patent 8609437 Patent 8580263 Patent 8329873 Patent 7332585 Patent 7332580 Patent 7129057 Patent 6946275 Patent 6617427

Abstract

The Biochemistry and Biotechnology Facility (BBF) makes available to Fox Chase Cancer Center (FCCC) investigators a group of state-of-the-art technologies for the identification, characterization, and utilization of genes, polymorphisms, transcripts, proteins; and peptides. The four components of BBF are all important and synergistic. DMA Synthesis delivers error-free oligonucleotides, regular, modified, or fluorescent probes, overnight with full quality control, Quantitative Real-time PCR provides high sensitivity and accuracy gene expression quantitation and distinguishes regulation by alternate transcripts. Mass Spectrometry identifies the components of protein complexes and supports biochemical, biophysical, and drug research. Proteomics reveals the global protein changes and modifications in response to disease states or drug treatments and discovers secondary targets of cancer-causing mutations. Anthony T. Yeung, Ph.D., (Biomolecular Structure and Function) directs BBF to provide uniformly high quality products at the cutting edge of performance. This is accomplished by proactive user interactions, and external collaborations with the leaders in each discipline. The Facility is used by 53 peer-reviewed investigators with 130 grants involving all three FCCC Divisions. About 95% of its use is by investigators with peer-reviewed funding. During the last grant period, demands on DNA synthesis (700 oligonucleotides per month by 2003) and Mass Spectrometry (about 22 projects in 2003) have both doubled. In addition, new services of Quantitative Real-time PCR and Proteomics have been developed in BBF because they are critical technologies for cancer research and are used by 13 and 7 investigators, respectively. In 2003, DNA Synthesis has contributed to 48 peer-reviewed, funded investigators, Quantitative Real-time PCR, 14; Mass Spectrometry, 23; and Proteomics, 7. BBF personnel have in-depth understanding of the science of the users and facilitate their research as highly integrated tools and participants of these research programs.

View original record on NIH RePORTER →